Table 2 Carrier frequency of KIR+HLA class I ligand combinations in breast cancer patients and controls.

From: Coexistence of inhibitory and activating killer-cell immunoglobulin-like receptors to the same cognate HLA-C2 and Bw4 ligands confer breast cancer risk

KIR- HLA combination

Healthy controls (n = 278)

Breast cancer

Comparison

All (n = 162)

Advanced (n = 44)

Early (n = 70)

All versus controls

Advanced versus controls

p value

OR (95% CI)

p value

OR (95% CI)

%F

(N +)

%F

(N +)

%F

(N +)

Inhibitory KIR + HLA class I ligand

2DL1 + C2 + 

74.7

(192/256)

67.9

(93/135)

79.5

(31/38)

57.9

(33/56)

    

2DL2 + 2DL3 + C1 + 

34.6

(92/256)

32.7

(50/140)

35.7

(15/38)

29.7

(19/56)

    

3DL1 + Bw4 + 

60.6

(143/233)

50.8

(62/116)

58.8

(20/32)

51.0

(26/48)

    

3DL2 + A3/A11 + 

40.0

(50/125)

42.4

(39/92)

31.8

(7/22)

37.8

(14/37)

    

Activating KIR + HLA class I ligand

2DS1 + C2 + 

26.9

(73/256)

36.1

(53/135)

52.4

(22/38)

21.0

(13/56)

  

0.001

2.98 (1.54 to 5.79)

3DS1 + Bw4 + 

17.7

(46/233)

25.9

(37/116)

29.3

(12/32)

18.6

(11/48)

  

0.008

2.6 (1.26 to 5.39)

Inhibitory KIR + Activating KIR + HLA class I ligand

2DL1 + C2 + 2DS1 + 

26.6

(72/256)

34.5

(51/135)

52.4

(22/38)

19.0

(2/56)

  

0.001

3.04 (1.56 to 5.89)

2DL1 + C2 + 2DS1 − 

45.5

(120/256)

27.8

(42/135)

22.0

(9/38)

32.8

(21/56)

0.0004

0.46 (0.3 to 0.71)

0.005

0.34 (0.15 to 0.73)

3DL1 + Bw4 + 3DS1 + 

15.6

(41/233)

20.1

(30/116)

29.3

(12/32)

14.5

(9/48)

  

0.033

2.23 (1.05 to 4.72)

3DL1 + Bw4 + 3DS1-

40.5

(102/233)

23.7

(32/116)

21.6

(8/32)

28.8

(17/48)

0.001

0.46 (0.28 to 0.73)

0.027

0.41 (0.18 to 0.92)

2DL1 + C2 + 3DL1 + Bw4 + 2DS1 + 3DS1 + 

11.5

(30/233)

12.3

(19/116)

19.5

(8/32)

4.6

(3/48)

    

2DL1 + C2 + 3DL1 + Bw4 + 2DS1 − 3DS1 − 

25.9

(66/233)

12.8

(19/116)

12.5

(5/32)

16.1

(10/48)

0.002

0.42 (0.24 to 0.73)